STOCKHOLM, Dec. 9, 2022
/PRNewswire/ -- Calliditas Therapeutics AB (publ)
("Calliditas") today announced that it will host a fireside chat
with its commercial partner Everest Medicines (HKEX 1952.HK,
"Everest") on Wednesday, December 14th,
2022 at 8am Eastern Time
(2pm Central European Time,
8pm China Standard Time).
The fireside chat will feature an introduction to Rogers
Yongqing Luo, Everest's new CEO, and a presentation from Dr
Zhengying Zhu, Everest's Chief
Medical Officer, Internal Medicine, who will discuss the IgA
nephropathy (IgAN) disease landscape and market in China, the NefIgArd clinical trial, and
Everest's strategic plans in the renal space. There will then be a
Q&A session.
To register, please click here.
Calliditas entered into a license agreement with Everest to
develop and commercialize Nefecon in Greater China and Singapore in IgAN in 2019 and expanded the
agreement to include South Korea
in March 2022. Everest's New Drug
Application (NDA) for Nefecon was accepted for review by the
Chinese regulatory authority National Medical Products
Administration (NMPA) in November
2022.
For further information, please contact:
Marie Galay, IR Manager,
Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on December 9, 2022 at 8:00
a.m. CET.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, developed under the name Nefecon, has been granted
accelerated approval by the FDA under the trade name TARPEYO® and
conditional marketing authorization by the European Commission
under the trade name Kinpeygo®. Kinpeygo is being commercialized in
the European Union Member States by Calliditas' partner, STADA
Arzneimittel AG. Additionally, Calliditas is conducting a
Phase 2b/3 clinical trial in primary
biliary cholangitis and a Phase 2 proof-of-concept trial in head
and neck cancer with its NOX inhibitor product candidate,
setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm
(ticker: CALTX) and its American Depositary Shares are listed on
the Nasdaq Global Select Market (ticker: CALT).
The following files are available for download:
https://mb.cision.com/Main/16574/3679873/1724805.pdf
|
Everest Webinar
Eng
|
View original
content:https://www.prnewswire.com/news-releases/calliditas-to-host-fireside-chat-with-its-china-commercial-partner-everest-medicines-301699025.html
SOURCE Calliditas Therapeutics